Literature DB >> 2941176

A new triphenylethylene compound, Fc-1157a. I. Hormonal effects.

S Kallio, L Kangas, G Blanco, R Johansson, A Karjalainen, M Perilä, I Pippo, H Sundquist, M Södervall, R Toivola.   

Abstract

The basic pharmacological and biochemical properties of a new antiestrogen, Fc-1157a, are described. Fc-1157a is bound specifically and with high affinity to estrogen receptors. The binding is competitive with estradiol. Fc-1157a treatment induces translocation of estrogen receptors from cytoplasm to nucleus. The turnover rate of nuclear estrogen receptors is markedly lower than with estradiol, but is more rapid than after tamoxifen. Fc-1157a is an almost pure antiestrogen in rat uterus, but has intrinsic estrogenic activity in mouse uterus. In animal experiments Fc-1157a has shown antitumor properties, which are described in the companion paper.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2941176     DOI: 10.1007/bf00306736

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  37 in total

Review 1.  Current models of steroid hormone action: a critique.

Authors:  J Gorski; F Gannon
Journal:  Annu Rev Physiol       Date:  1976       Impact factor: 19.318

2.  Studies on the mechanism of action of the nonsteroidal antioestrogen tamoxifen (I.C.I. 46,474) in the rat.

Authors:  V C Jordan; C J Dix; L Rowsby; G Prestwich
Journal:  Mol Cell Endocrinol       Date:  1977-04       Impact factor: 4.102

3.  An improved assay for nuclear estrogen receptor in experimental and human breast cancer.

Authors:  R E Garola; W L McGuire
Journal:  Cancer Res       Date:  1977-09       Impact factor: 12.701

4.  Specific estrogen binding by the cytoplasm fof human breast carcinoma.

Authors:  S G Korenman; B A Dukes
Journal:  J Clin Endocrinol Metab       Date:  1970-05       Impact factor: 5.958

5.  New model for steroid hormone receptors?

Authors:  W T Schrader
Journal:  Nature       Date:  1984 Mar 1-7       Impact factor: 49.962

6.  Nuclear mechanisms of estrogen action. Effects of estradiol and anti-estrogens on estrogen receptors and nuclear receptor processing.

Authors:  K B Horwitz; W L McGuire
Journal:  J Biol Chem       Date:  1978-11-25       Impact factor: 5.157

Review 7.  Current status of estrogen and progesterone receptors in breast cancer.

Authors:  W L McGuire; K B Horwitz; O H Pearson; A Segaloff
Journal:  Cancer       Date:  1977-06       Impact factor: 6.860

8.  Microsomal binding sites for nonsteroidal anti-estrogens in MCF 7 human mammary carcinoma cells. Demonstration of high affinity and narrow specificity for basic ether derivatives of triphenylethylene.

Authors:  C K Watts; L C Murphy; R L Sutherland
Journal:  J Biol Chem       Date:  1984-04-10       Impact factor: 5.157

9.  Estrogen receptor-mediated and cytotoxic effects of the antiestrogens tamoxifen and 4-hydroxytamoxifen.

Authors:  C M Taylor; B Blanchard; D T Zava
Journal:  Cancer Res       Date:  1984-04       Impact factor: 12.701

10.  Activated oestrogen receptors in breast cancer and response to endocrine therapy.

Authors:  M D Fernandez; J I Burn; P D Sauven; G Parmar; J O White; L Myatt
Journal:  Eur J Cancer Clin Oncol       Date:  1984-01
View more
  17 in total

Review 1.  Toremifene in postmenopausal breast cancer. Efficacy, safety and cost.

Authors:  J U Mäenpää; S L Ala-Fossi
Journal:  Drugs Aging       Date:  1997-10       Impact factor: 3.923

2.  Effects of the antiestrogen toremifene on growth of the human mammary carcinoma cell line MCF-7.

Authors:  R Grenman; K M Laine; P J Klemi; S Grenman; D J Hayashida; H Joensuu
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 3.  Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer.

Authors:  L R Wiseman; K L Goa
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

Review 4.  Comparative tolerability of first-generation selective estrogen receptor modulators in breast cancer treatment and prevention.

Authors:  M G Curtis
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

5.  Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer.

Authors:  V J Wiebe; C C Benz; I Shemano; T B Cadman; M W DeGregorio
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Effect of combined therapy with the antiestrogen agent toremifene and local hyperthermia on breast cancer cells implanted in nude mice.

Authors:  Yoshiaki Kanaya; Hiroyoshi Doihara; Kouji Shiroma; Yutaka Ogasawara; Hiroshi Date
Journal:  Surg Today       Date:  2008-09-27       Impact factor: 2.549

7.  Phase I clinical and pharmacokinetics study of high-dose toremifene in postmenopausal patients with advanced breast cancer.

Authors:  J Bishop; R Murray; L Webster; P Pitt; K Stokes; A Fennessy; I Olver; G Leber
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Effect of toremifene on the growth, hormone receptors and insulin-like growth factor-1 of hormone-dependent MCF-7 tumors in athymic mice.

Authors:  Y Iino; Y Takai; T Ando; N Sugamata; M Maemura; T Takeo; S Ohwada; Y Morishita
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  High dose toremifene for estrogen and progesterone receptor negative metastatic breast cancer: a phase II trial of the Cancer and Leukemia Group B (CALGB).

Authors:  J J Perry; D A Berry; R B Weiss; D M Hayes; D B Duggan; I C Henderson
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

10.  Evaluating the response to antioestrogen toremifene treatment in DMBA induced rat mammary carcinoma.

Authors:  R Huovinen; P L Kellokumpu-Lehtinen; Y Collan
Journal:  Int J Exp Pathol       Date:  1994-08       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.